Suven Life Sciences today said that it has been granted a product patent by Canada corresponding to New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The patents are valid till 2033, the company said in a BSE filing.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
The granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntingtons disease, Parkinson's and Schizophrenia.
Suven Life Sciences shares were trading 0.23 per cent down at Rs 172.25 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
